WUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection

Deep News07-09

Shares of WUXI BIO (02269) surged more than 6% during the trading session. At the time of writing, the stock was up 4.99%, trading at HK$37.44 with a turnover of HK$660 million.

The company announced that its biologics drug substance manufacturing facility eight (MFG8), located at its Shijiazhuang base in Hebei, has successfully passed a Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA). This clearance supports the commercial production of a therapy for autoimmune diseases.

Dr. Chris Chen, Chief Executive Officer of WUXI BIO, stated that passing this FDA PLI not only validates the company's ongoing commitment to building a world-class quality system but also demonstrates its reliable capability to support partners in advancing global commercial production. He expressed pleasure in leveraging high-standard production capabilities to help bring this potential "blockbuster" innovative autoimmune therapy closer to commercial supply and contribute to improving access to high-quality biologics. WUXI BIO will continue to empower global partners with its dependable quality system to accelerate the delivery of innovative biologics to more patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113008372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113008372","market":"nz","top_or_hot":-1,"title":"WUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection","media":"Deep News","content":"<p>Shares of <b>WUXI BIO</b> (<b>02269</b>) surged more than 6% during the trading session. At the time of writing, the stock was up 4.99%, trading at HK$37.44 with a turnover of HK$660 million.<br><br>\nThe company announced that its biologics drug substance manufacturing facility eight (MFG8), located at its Shijiazhuang base in Hebei, has successfully passed a Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA). This clearance supports the commercial production of a therapy for autoimmune diseases.<br><br>\nDr. Chris Chen, Chief Executive Officer of WUXI BIO, stated that passing this FDA PLI not only validates the company's ongoing commitment to building a world-class quality system but also demonstrates its reliable capability to support partners in advancing global commercial production. He expressed pleasure in leveraging high-standard production capabilities to help bring this potential \"blockbuster\" innovative autoimmune therapy closer to commercial supply and contribute to improving access to high-quality biologics. WUXI BIO will continue to empower global partners with its dependable quality system to accelerate the delivery of innovative biologics to more patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-09 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>WUXI BIO</b> (<b>02269</b>) surged more than 6% during the trading session. At the time of writing, the stock was up 4.99%, trading at HK$37.44 with a turnover of HK$660 million.<br><br>\nThe company announced that its biologics drug substance manufacturing facility eight (MFG8), located at its Shijiazhuang base in Hebei, has successfully passed a Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA). This clearance supports the commercial production of a therapy for autoimmune diseases.<br><br>\nDr. Chris Chen, Chief Executive Officer of WUXI BIO, stated that passing this FDA PLI not only validates the company's ongoing commitment to building a world-class quality system but also demonstrates its reliable capability to support partners in advancing global commercial production. He expressed pleasure in leveraging high-standard production capabilities to help bring this potential \"blockbuster\" innovative autoimmune therapy closer to commercial supply and contribute to improving access to high-quality biologics. WUXI BIO will continue to empower global partners with its dependable quality system to accelerate the delivery of innovative biologics to more patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516422366.SGD","symbol_name":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","start_time":0,"source_url":"","article_id":"1113008372","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113008372","pubTimestamp":1783566724,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of WUXI BIO (02269) surged more than 6% during the trading session. At the time of writing, the stock was up 4.99%, trading at HK$37.44 with a turnover of HK$660 million. The company announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","BK1521":"挪威政府全球养老基金持仓","LU0051755006.USD":"摩根大通中国A (dist)","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","BK1589":"北水核心资产","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","BK4588":"碎股","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","02269":"药明生物","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1141":"生命科学工具和服务","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","BK1576":"医药外包概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1610":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0823426480.USD":"法巴中国股票经典Dis","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","BK4585":"ETF&股票定投概念","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","IPOS":"Renaissance International IPO ETF","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD"},"translate_title":"MFG8工厂通过FDA关键批准前检查，药明生物股价飙升逾6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":1,"02269":1,"IPOS":1,"LABU":1},"content_text":"Shares of WUXI BIO (02269) surged more than 6% during the trading session. At the time of writing, the stock was up 4.99%, trading at HK$37.44 with a turnover of HK$660 million.\nThe company announced that its biologics drug substance manufacturing facility eight (MFG8), located at its Shijiazhuang base in Hebei, has successfully passed a Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA). This clearance supports the commercial production of a therapy for autoimmune diseases.\nDr. Chris Chen, Chief Executive Officer of WUXI BIO, stated that passing this FDA PLI not only validates the company's ongoing commitment to building a world-class quality system but also demonstrates its reliable capability to support partners in advancing global commercial production. He expressed pleasure in leveraging high-standard production capabilities to help bring this potential \"blockbuster\" innovative autoimmune therapy closer to commercial supply and contribute to improving access to high-quality biologics. WUXI BIO will continue to empower global partners with its dependable quality system to accelerate the delivery of innovative biologics to more patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113008372","isCrawlerRequest":true}